Marktanalyse - Postmenopausal Vaginal Atrophy Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Postmenopausal Vaginal Atrophy Therapeutics - Pipeline Assessment and Market Forecasts to 2019


Summary


GlobalData, the industry analysis specialist, has released its new report, 'Postmenopausal Vaginal Atrophy Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Postmenopausal Vaginal Atrophy Therapeutics market. The report identifies the key trends shaping and driving the global Postmenopausal Vaginal Atrophy Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Postmenopausal Vaginal Atrophy Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.


Scope

The report provides information on the key drivers and challenges of the Postmenopausal Vaginal Atrophy Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Postmenopausal Vaginal Atrophy Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Postmenopausal Vaginal Atrophy Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Postmenopausal Vaginal Atrophy Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Postmenopausal Vaginal Atrophy Therapeutics market


Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Postmenopausal Vaginal Atrophy Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Postmenopausal Vaginal Atrophy Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Postmenopausal Vaginal Atrophy Therapeutics market landscape? — Identify, understand and capitalize.


Press Release:

GlobalData, the industry analysis specialist, has released its new report, 'Postmenopausal Vaginal Atrophy Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information on the global postmenopausal vaginal atrophy therapeutics market, and provides analysis of a number of key areas. The report identifies the key trends shaping and driving the global postmenopausal vaginal atrophy therapeutics market and provides insights into the current competitive landscape and emerging companies expected to significantly alter the market positioning of current market leaders. Most importantly, the report provides valuable insights into the pipeline products within the global postmenopausal vaginal atrophy sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Postmenopausal Vaginal Atrophy Therapeutics Market is Forecast to Witness High Growth until 2019

GlobalData’s analysis indicates that the global postmenopausal vaginal atrophy therapeutics market was worth $1,634.5m in 2011, after increasing at a Compound Annual Growth Rate (CAGR) of 8.0% during 2006-2011.The market is expected to grow at a CAGR of 8.5% during 2011-2019 to $3,144.3m in 2019. Estrogen Replacement Therapy (ERT) is the mainstay of treatment for postmenopausal vaginal atrophy patients. The currently used treatment options can be divided into four categories: vaginal cream, vaginal tablets, vaginal rings and oral estradiol, all of which are types of ERT. Estrace cream (estradiol) by Warner Chilcott and Premarin cream (conjugated estradiol) by Pfizer are examples of vaginal creams, while Vagifem (estradiol) is a vaginal tablet and is marketed by Novo Nordisk. Femring (estradiol, extended release) by Warner Chilcott and Estring (estradiol acetate, extended release) by Pfizer are types of vaginal ring. Oral estradiol is least preferred treatment option because its usage is associated with adverse events such as deep vein thrombosis, Coronary Heart Disease (CHD), stroke, and invasive breast cancer. Of these treatment options, vaginal cream and vaginal tablets are most widely used. The growth witnessed during 2006-2011 was due to increasing awareness of postmenopausal vaginal atrophy among patients and physicians, which resulted in increased diagnosis and treatment rates. The market is expected to show high growth during the forecast period (2011-2019) due to the expected launch of Phase III FIC pipeline molecules Vaginorm (dehydroepiandrosterone) and Ophena (ospemifene) in the US. They will further improve patient compliance through improved safety and efficacy profiles and therefore drive market growth during the forecast period.

Safety Concern, Low Diagnosis and Low Levels of Treatment-seeking Behavior are the Main Unmet Needs

GlobalData’s analysis suggests that postmenopausal vaginal atrophy therapeutics market has significant unmet need in terms of a low diagnosis rate, low levels of treatment-seeking behavior among menopausal women, and safety concerns associated with ERT. The vaginal ring drug class has already been issued a black box warning by the US Food and Drug Administration (FDA). With regards to diagnosis, women are often reluctant to discuss symptoms such as vaginal dryness, vaginal burning and discomfort during intercourse with healthcare professionals, leading to a low diagnosis rate and low treatment-seeking rate. ERT is associated with a number of adverse effects. Usage may lead to endometrial cancer, cardiovascular disorders, breast cancer and dementia. This significant unmet is likely to be fulfilled in the future by the launch of Vaginorm and Ophena, which have better safety and efficacy profiles and will further drive the postmenopausal vaginal atrophy therapeutics market.

Current Competition in the Postmenopausal Vaginal Atrophy Therapeutics Market is Weak

GlobalData’s analysis suggests that current competition in the postmenopausal vaginal atrophy therapeutics market is weak because it is dominated by products such as Premarin, Estrace, Vagifem, Femring and Estring, all of which are types of ERT.

These products are associated with a number of adverse events which cause poor patient compliance and present significant concerns to physicians treating postmenopausal vaginal atrophy. Premarin, Vagifem and Estrace are the most widely prescribed drugs. Vaginal cream and vaginal tablets are more convenient to use than vaginal rings, and they are associated with fewer adverse events than oral estrogen therapy (systemic). Thus, vaginal cream and vaginal tablets are the preferred modes of treatment.

The Pipeline of Postmenopausal Vaginal Atrophy Therapeutics Market is Strong with Predicted Launch of Two First-in-Class Molecules

GlobalData’s analysis shows that the postmenopausal vaginal atrophy therapeutics pipeline is strong with nine molecules in various Phases of development. There are three molecules in Phase III, one molecule in Phase II, one molecule in Phase I and three molecules in the Pre-clinical Phase. There is one molecule for which the Phase of development is unknown.

Two of the molecules in Phase III, Vaginorm and Ophena, are company-sponsored, First-in-Class (FIC) and have displayed good levels of safety and efficacy in clinical studies. Both are expected to enter the US market in 2014. Vaginorm is a type of Dehydroepiandrosterone Replacement (DHEAR) therapy, while Ophena is a Selective Estrogen Receptor Modulator (SERM). ERT is the only treatment option for postmenopausal vaginal atrophy patients, but the launch of Ophena and Vaginorm will have a significant impact on the treatment pattern.

Overall, these two late stage FIC pipeline molecules will fulfill some of the unmet need in the postmenopausal vaginal atrophy therapeutics market.

1 Table of Contents

1 Table of Contents 3

1.1 List of Tables 5

1.2 List of Figures 6

2 Postmenopausal Vaginal Atrophy Therapeutics - Introduction 7

2.1 Disease Overview 7

2.2 Epidemiology 7

2.3 Etiology 7

2.4 Pathophysiology 8

2.5 Signs and Symptoms 8

2.6 Diagnosis 8

2.6.1 Laboratory Diagnosis Tests 8

2.7 Treatment and Management Options 9

2.7.1 Vaginal Cream 9

2.7.2 Estradiol Ring 9

2.7.3 Vaginal Tablet 9

2.8 GlobalData Pipeline Report Guidance 10

3 Postmenopausal Vaginal Atrophy Therapeutics - Market Characterization 11

3.1 Postmenopausal Vaginal Atrophy Therapeutics Market Size (2006-2011) - Global 11

3.2 Postmenopausal Vaginal Atrophy Therapeutics Market Forecast (2011-2019) - Global 13

3.3 Postmenopausal Vaginal Atrophy Therapeutics Market Size (2006-2011) - The US 14

3.4 Postmenopausal Vaginal Atrophy Therapeutics Market Forecast (2011-2019) - The US 15

3.5 Postmenopausal Vaginal Atrophy Therapeutics Market Size (2006-2011) - France 16

3.6 Postmenopausal Vaginal Atrophy Therapeutics Market Forecast (2011-2019) - France 17

3.7 Postmenopausal Vaginal Atrophy Therapeutics Market Size (2006-2011) - Germany 18

3.8 Postmenopausal Vaginal Atrophy Therapeutics Market Forecast (2011-2019) - Germany 19

3.9 Postmenopausal Vaginal Atrophy Therapeutics Market Size (2006-2011) - Italy 20

3.10 Postmenopausal Vaginal Atrophy Therapeutics Market Forecast (2011-2019) - Italy 21

3.11 Postmenopausal Vaginal Atrophy Therapeutics Market Size (2006-2011) - Spain 22

3.12 Postmenopausal Vaginal Atrophy Therapeutics Market Forecast (2011-2019) - Spain 23

3.13 Postmenopausal Vaginal Atrophy Therapeutics Market Size (2006-2011) - The UK 24

3.14 Postmenopausal Vaginal Atrophy Therapeutics Market Forecast (2011-2019) - The UK 25

3.15 Postmenopausal Vaginal Atrophy Therapeutics Market Size (2006-2011) - Japan 26

3.16 Postmenopausal Vaginal Atrophy Therapeutics Market Forecast (2011-2019) - Japan 27

3.17 Drivers and Barriers for the Postmenopausal Vaginal Atrophy Therapeutics Market 28

3.17.1 Drivers for the Postmenopausal Vaginal Atrophy Therapeutics Market 28

3.17.2 Barriers to the Postmenopausal Vaginal Atrophy Therapeutics Market 28

3.18 Opportunity and Unmet Need Analysis 29

3.19 Key Takeaway 29

4 Postmenopausal Vaginal Atrophy Therapeutics - Competitive Assessment 30

4.1 Overview 30

4.2 Strategic Competitor Assessment 30

4.3 Product Profiles for the Major Marketed Products in the Postmenopausal Vaginal Atrophy Therapeutics Market 31

4.3.1 Vaginal Cream 31

4.3.2 Estrace 31

4.3.3 Premarin 31

4.3.4 Vaginal Ring 32

4.3.5 Estring 32

4.3.6 Femring 33

4.3.7 Vaginal Tablet 34

4.3.8 Vagifem 34

4.4 Key Takeaway 35

5 Postmenopausal Vaginal Atrophy Therapeutics - Pipeline Assessment 36

5.1 Overview 36

5.2 Strategic Pipeline Assessment 36

5.3 Postmenopausal Vaginal Atrophy Therapeutics Pipeline - Pipeline by Phase of Development 36

5.3.1 Postmenopausal Vaginal Atrophy Therapeutics - Phase III Pipeline 36

5.3.2 Postmenopausal Vaginal Atrophy Therapeutics - Phase II Pipeline 37

5.3.3 Postmenopausal Vaginal Atrophy Therapeutics - Phase I Pipeline 37

5.3.4 Postmenopausal Vaginal Atrophy Therapeutics - Pre-Clinical Pipeline 37

5.3.5 Postmenopausal Vaginal Atrophy Therapeutics - Unknown Phase 37

5.3.6 Technology Trends Analytic Framework 38

5.4 Postmenopausal Vaginal Atrophy Therapeutics Market - Pipeline by Mechanism of Action 40

5.5 Postmenopausal Vaginal Atrophy Therapeutics - Promising Drugs under Clinical Development 40

5.6 Molecule Profile for Promising Drugs under Clinical Development 41

5.6.1 Ophena (ospemifene) 41

5.6.2 Vaginorm (dehydroepiandrosterone) 41

5.7 Key Takeaway 42

6 Postmenopausal Vaginal Atrophy Therapeutics - Clinical Trials Mapping 43

6.1 Clinical Trials by Region/Country (The US, EU5 and Japan) 43

6.2 Clinical Trials by Phase 44

6.3 Clinical Trials by Trial Status 45

6.4 Prominent Sponsors 46

6.5 Clinical Trials by Overall Sponsors 47

6.6 Top Companies Participating in Postmenopausal Vaginal Atrophy Therapeutics Clinical Trials 48

7 Postmenopausal Vaginal Atrophy Therapeutics - Strategic Assessment 49

7.1 Key Events Impacting the Future Market 49

7.2 Postmenopausal Vaginal Atrophy Therapeutics - Implications for Future Market Competition 50

8 Postmenopausal Vaginal Atrophy Therapeutics - Future Players 51

8.1 Introduction 51

8.2 Company Profiles 51

8.2.1 Bionovo, Inc. (Bionovo) 51

8.2.2 QuatRx Pharmaceutical Company 53

8.2.3 Shionogi & Co. 53

8.2.4 EndoCeutics, Inc 54

8.2.5 Bayer AG 54

8.2.6 Other Companies in Postmenopausal Vaginal Atrophy Therapeutics Market 55

9 Postmenopausal Vaginal Atrophy Therapeutics - Appendix 56

9.1 Market Definitions 56

9.2 Acronyms 56

9.3 Methodology 56

9.3.1 Coverage 57

9.3.2 Secondary Research 57

9.3.3 Forecasting 57

9.3.4 Primary Research 60

9.3.5 Expert Panel Validation 60

9.4 Contact Us 60

9.5 Disclaimer 60

9.6 Bibliography 61





1.1 List of Tables

Table 1: Postmenopausal Vaginal Atrophy Prevalence in The US, EU5 and Japan 7

Table 2: Treatment Options for Postmenopausal Vaginal Atrophy 9

Table 3: Postmenopausal Vaginal Atrophy Therapeutics Market, Global, Revenue ($m), 2006-2011 12

Table 4: Postmenopausal Vaginal Atrophy Therapeutics Market, Global, Forecast ($m), 2011-2019 13

Table 5: Postmenopausal Vaginal Atrophy Therapeutics Market, The US, Revenue ($m), 2006-2011 14

Table 6: Postmenopausal Vaginal Atrophy Therapeutics Market, The US, Forecast ($m), 2011-2019 15

Table 7: Postmenopausal Vaginal Atrophy Therapeutics Market, France, Revenue ($m), 2006-2011 16

Table 8: Postmenopausal Vaginal Atrophy Therapeutics Market, France, Forecast ($m), 2011-2019 17

Table 9: Postmenopausal Vaginal Atrophy Therapeutics Market, Germany, Revenue ($m), 2006-2011 18

Table 10: Postmenopausal Vaginal Atrophy Therapeutics Market, Germany, Forecast ($m), 2010-2019 19

Table 11: Postmenopausal Vaginal Atrophy Therapeutics Market, Italy, Revenue ($m), 2006-2011 20

Table 12: Postmenopausal Vaginal Atrophy Therapeutics Market, Italy, Forecast ($m), 2011-2019 21

Table 13: Postmenopausal Vaginal Atrophy Therapeutics Market, Spain, Revenue ($m), 2006-2011 22

Table 14: Postmenopausal Vaginal Atrophy Therapeutics Market, Spain, Forecast ($m), 2011-2019 23

Table 15: Postmenopausal Vaginal Atrophy Therapeutics Market, The UK, Revenue ($m), 2006-2011 24

Table 16: Postmenopausal Vaginal Atrophy Therapeutics Market, The UK, Forecast ($m), 2011-2019 25

Table 17: Postmenopausal Vaginal Atrophy Therapeutics Market, Japan, Revenue ($m), 2006-2011 26

Table 18: Postmenopausal Vaginal Atrophy Therapeutics Market, Japan, Forecast ($m), 2011-2019 27

Table 19: Postmenopausal Vaginal Atrophy Therapeutics - Phase III Pipeline, 2011 36

Table 20: Postmenopausal Vaginal Atrophy Therapeutics - Phase II Pipeline, 2011 37

Table 21: Postmenopausal Vaginal Atrophy Therapeutics - Phase I Pipeline, 2011 37

Table 22: Postmenopausal Vaginal Atrophy Therapeutics - Pre-Clinical Pipeline, 2011 37

Table 23: Postmenopausal Vaginal Atrophy Therapeutics - Unknown Phase, 2011 37

Table 24: Postmenopausal Vaginal Atrophy Therapeutics - Most Promising Drugs Under Clinical Development, 2011 40

Table 25: Postmenopausal Vaginal Atrophy Therapeutics Market - Clinical Trials by Country, 2011 43

Table 26: Postmenopausal Vaginal Atrophy Therapeutics - Clinical Trials by Phase, 2011 44

Table 27: Postmenopausal Vaginal Atrophy Therapeutics - Clinical Trials by Status, 2011 45

Table 28: Postmenopausal Vaginal Atrophy Therapeutics - Prominent Sponsors, 2011 46

Table 29: Postmenopausal Vaginal Atrophy Therapeutics - Overall Sponsors, 2011 47

Table 30: Postmenopausal Vaginal Atrophy Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011 48

Table 31 Bionovo Inc., Women’s Healthcare Pipeline, 2011 52

Table 32: QuatRx Pharmaceuticals Company, Women’s Healthcare Pipeline, 2011 53

Table 33: Shionogi Pharmaceuticals - Women’s Healthcare Pipeline, 2011 53

Table 34: EndoCeutics - Women’s Healthcare Pipeline, 2011 54

Table 35 Bayer AG - Women’s Healthcare Pipeline, 2011 55

Table 36: Postmenopausal Vaginal Atrophy Therapeutics Market - Future Players 55





1.2 List of Figures

Figure 1: Postmenopausal Vaginal Atrophy Therapeutics Market, Global, Revenue ($m), 2006-2011 11

Figure 2: Postmenopausal Vaginal Atrophy Therapeutics Market, Global, Forecast ($m), 2011-2019 13

Figure 3: Postmenopausal Vaginal Atrophy Therapeutics Market, The US, Revenue ($m), 2006-2011 14

Figure 4: Postmenopausal Vaginal Atrophy Therapeutics Market, The US, Forecast ($m), 2011-2019 15

Figure 5: Postmenopausal Vaginal Atrophy Therapeutics Market, France, Revenue ($m), 2006-2011 16

Figure 6: Postmenopausal Vaginal Atrophy Therapeutics Market, France, Forecast ($m), 2011-2019 17

Figure 7: Postmenopausal Vaginal Atrophy Therapeutics Market, Germany, Revenue ($m), 2006-2011 18

Figure 8: Postmenopausal Vaginal Atrophy Therapeutics Market, Germany, Forecast ($m), 2011-2019 19

Figure 9: Postmenopausal Vaginal Atrophy Therapeutics Market, Italy, Revenue ($m), 2006-2011 20

Figure 10: Postmenopausal Vaginal Atrophy Therapeutics Market, Italy, Forecast ($m), 2011-2019 21

Figure 11: Postmenopausal Vaginal Atrophy Therapeutics Market, Spain, Revenue ($m), 2006-2011 22

Figure 12: Postmenopausal Vaginal Atrophy Therapeutics Market, Spain, Forecast ($m), 2011-2019 23

Figure 13: Postmenopausal Vaginal Atrophy Therapeutics Market, The UK, Revenue ($m), 2006-2011 24

Figure 14: Postmenopausal Vaginal Atrophy Therapeutics Market, The UK, Forecast ($m), 2011-2019 25

Figure 15: Postmenopausal Vaginal Atrophy Therapeutics Market, Japan, Revenue ($m), 2006-2011 26

Figure 16: Postmenopausal Vaginal Atrophy Therapeutics Market, Japan, Forecast ($m), 2011-2019 27

Figure 17: Opportunity and Unmet Need in the Postmenopausal Vaginal Atrophy Therapeutics Market, 2011 29

Figure 18: Postmenopausal Vaginal Atrophy Therapeutics - Strategic Competitor Assessment, 2011 30

Figure 19: Postmenopausal Vaginal Atrophy Therapeutics - Pipeline by Phase of Development, 2011 36

Figure 20: Postmenopausal Vaginal Atrophy Therapeutics - Technology Trends Analytics Framework, 2011 38

Figure 21: Postmenopausal Vaginal Atrophy Therapeutics - Technology Trends Analytics Framework - Description, 2011 39

Figure 22: Postmenopausal Vaginal Atrophy Therapeutics - Pipeline by Mechanism of Action, 2011 40

Figure 23: Postmenopausal Vaginal Atrophy Therapeutics - Clinical Trials by Country, 2011 43

Figure 24: Postmenopausal Vaginal Atrophy Therapeutics - Clinical Trials by Phase, 2011 44

Figure 25: Postmenopausal Vaginal Atrophy Therapeutics - Clinical Trials by Status, 2011 45

Figure 26: Postmenopausal Vaginal Atrophy Therapeutics - Prominent Sponsors, 2011 46

Figure 27: Postmenopausal Vaginal Atrophy Therapeutics - Overall Sponsors, 2011 47

Figure 28: Postmenopausal Vaginal Atrophy Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011 48

Figure 29: Postmenopausal Vaginal Atrophy Therapeutics Market - Drivers and Barriers, 2011 49

Figure 30: Implications for Future Market Competition in the Postmenopausal Vaginal Atrophy Market, 2011 50

Figure 31: Postmenopausal Vaginal Atrophy Therapeutics Market - Pipeline by Company, 2011 51

Figure 32: GlobalData Market Forecasting Model 59

• Female Hypoactive Sexual Desire Disorder – Pipeline Review, H1 2013
• Cervical Dysplasia – Pipeline Review, H1 2013
• EpiCast Report: Postmenopausal Vaginal Atrophy - Epidemiology Forecast to 2022
• Female Sexual Dysfunction – Pipeline Review, H1 2013
• Menopausal Disorders – Pipeline Review, H1 2013
• Menopausal Hot Flashes – Pipeline Review, H1 2013
• Uterine Fibroids – Pipeline Review, H1 2013
• Vaginal Atrophy (Atrophic Vaginitis) – Pipeline Review, H1 2013
• Contraceptives – Pipeline Review, H1 2013
• Dysmenorrhea – Pipeline Review, H1 2013
• Endometriosis – Pipeline Review, H1 2013
• Women Infertility – Pipeline Review, H1 2013
• Premature Labor (Tocolysis) – Pipeline Review, H2 2012
• Vasomotor Symptoms of Menopause – Pipeline Review, H2 2012
• Contraceptives Market to 2018 - Safety Concerns Plague Drospirenone-containing Birth Control Pills and Long-term Use of Estrogen
• Premature Ovarian Failure – Pipeline Review, H2 2012
• Premenstrual Syndrome – Pipeline Review, H2 2012
• Women’s Health Therapeutics Market to 2018 - Unmet Need for Safe and Effective Treatments due to Unfavorable Risk/Benefit Profile Associated with Hormone Replacement Therapy
• Endometriosis Global Clinical Trials Review, H2, 2012
• Primary Dysmenorrhea – Pipeline Review, H2 2012